Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes said today it acquired spinal nerve localization tech dev Innovative Surgical Solutions, which operates as Sentio, for an undisclosed amount.
Wixom, Mich.-based Sentio has developed a platform designed to provide real-time feedback of nerve location using adhesive sensors applied to the skin, DePuy Synthes said. The system can be set up by OR personnel and does not require a neuromonitoring specialist.
“With Sentio’s nerve localization technology, DePuy Synthes will strengthen its spine portfolio in decompression procedures as well as lateral surgery, and build a platform for future innovation in minimally invasive surgery. The surgeon-driven approach will also help us reach more customers operating in an ambulatory surgery setting. This acquisition underscores our commitment to investing in differentiated technologies that help us reach more customers and patients around the world,” group chair Ciro Römer said in a press release.
DePuy Synthes said it intends to fold the devices into its spinal business, and use its network to expand availability of Sentio’s technology platform.
Last month, DePuy Synthes touted 4-year data from a large registry study showing that its Attune knee implant had a lower revision rate than the overall rate for total knee replacement.
The study examined data from 10,605 Attune implantations in Britain’s National Joint Registry for England, Wales, Northern Ireland & the Isle of Man, finding that the revision rate for Attune was 1.3% at 4 years, compared with the registry’s 1.9% average. Just 46 of the Attune knee procedures required revision, DePuy Synthes said.
